Faculty profile

Alexandre Zlotta

ResearcherUniversity of Toronto

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Toronto directory, so their courses and email address may be missing. Find their university profile.

Alexandre Zlotta

Researcher

Health Sciences

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
11 publications in the last five years, latest in 2026.
Principal investigator on 1 research grant (1 CIHR), most recently in 2023.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Artificial Intelligence Clinically Significant Prostate Cancer Early Diagnosis Health Informatics Prostate Cancer Risk Calculator Urology

Latest papers

Addition of immune checkpoint inhibitors to intravesical BCG for high-risk BCG-naïve non-muscle invasive bladder cancer: Systematic review and meta-analysis.
BJUI compass · 2026
Prostate-specific antigen density does not predict metastatic disease on PSMA-PET in high-risk prostate cancer patients with negative conventional imaging.
Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2025
Percentage of free to total PSA as a biomarker of survival in metastatic castration-resistant prostate cancer.
BJU international · 2025

All 43 publications

Latest funding

Development, multi-ancestry international validation, algorithmic audit, and prospective silent trial evaluation of PRISM - A globally accessible, patient-oriented artificial intelligence-based model to predict the presence of clinically significant prostate cancer
CIHR · 2023 · Nominated PI
$462,824
Development of the first pre-operative serum exosomal miRNA test to guide treatment decision in prostate cancer
CIHR · 2018 · Co-investigator
$573,752
qTAP, A Novel Platform for Personalized Medicine in Cancer
CIHR · 2014 · Co-investigator
$88,800

All 5 grants and awards

43 publications.

Addition of immune checkpoint inhibitors to intravesical BCG for high-risk BCG-naïve non-muscle invasive bladder cancer: Systematic review and meta-analysis.

Titus RS, Riveros C, Velasquez EL, Nguyen DD, Somawardana S, Singh A, Kaushik D, Sonpavde G, Zlotta A, Kulkarni G, Sridhar SS, Wallis CJD, Satkunasivam R

BJUI compass2026

DOI: 10.1002/bco2.70194 PMID: 42022227

Prostate-specific antigen density does not predict metastatic disease on PSMA-PET in high-risk prostate cancer patients with negative conventional imaging.

Kumar R, Lajkosz K, Metser U, Misurka J, Hiemstra J, Kreidstein J, Calicchia L, Silberman A, Finelli A, Fleshner NE, Hamilton RJ, Kulkarni GS, Zlotta A, Berlin A, Perlis N

Canadian Urological Association journal = Journal de l'Association des urologues du Canada2025

DOI: 10.5489/cuaj.9113 PMID: 40392159

Percentage of free to total PSA as a biomarker of survival in metastatic castration-resistant prostate cancer.

Silagy AW, Woon DTS, Kostos L, Bernardino R, Yiu TW, Wettstein MS, Goldberg H, Herrera-Cáceres JO, Shiakh H, Nason G, Zlotta A, Diamantis E, Bolton D, Fleshner N

BJU international2025

DOI: 10.1111/bju.16751 PMID: 40275794

Optimizing biopsy decisions in PI-RADS 3 lesions: cross-institutional validation of a local clinical risk model.

Deniffel D, Perlis N, Ghai S, Salinas-Miranda E, Namdar K, Klotz LH, Zlotta A, Finelli A, Haider MA

World journal of urology2025

DOI: 10.1007/s00345-025-05649-7 PMID: 40293532

Metabolic, cardiac, and bone health testing in patients with prostate cancer on androgen‐deprivation therapy: A population‐based assessment of adherence to therapeutic monitoring guidelines

Mousa A, Nguyen D, Lalani A, Satkunasivam R, Aminoltejari K, Hird A, Roy S, Morgan SC, Malone S, Kokorovic A

Cancer20254 citations

DOI: 10.1002/cncr.35606

Cost of Bladder Cancer Care: A Single-center Comparison of Radical Cystectomy and Trimodal Therapy.

Magee DE, Cheung DC, Hird AE, Chung P, Warde P, Catton C, Berlin A, Zlotta A, Fleshner NE, Kulkarni GS

Urology practice2023

DOI: 10.1097/upj.0000000000000403 PMID: 37103562

Validating the total cancer location density metric for stratifying patients with low-risk localized prostate cancer at higher risk of grade group reclassification while on active surveillance.

Tan GH, Deniffel D, Finelli A, Wettstein M, Ahmad A, Zlotta A, Fleshner N, Hamilton R, Kulkarni G, Nason G, Ajib K, Herrera-Caceres J, Chandrasekar T, Perlis N

Urologic oncology2023

DOI: 10.1016/j.urolonc.2022.12.003 PMID: 36639336

Prostate biopsy in the era of MRI-targeting: towards a judicious use of additional systematic biopsy.

Deniffel D, Perlis N, Ghai S, Girgis S, Healy GM, Fleshner N, Hamilton R, Kulkarni G, Toi A, van der Kwast T, Zlotta A, Finelli A, Haider MA

European radiology2022

DOI: 10.1007/s00330-022-08822-3 PMID: 35507051

Factors Associated with Stent Change and Prognosis in Patients with Malignant Ureteral Obstruction.

Gandhi S, Koziarz A, Finelli A, Fleshner N, Hamilton RJ, Kulkarni G, Perlis N, Zlotta A, Lajkosz K, Lee JY

Journal of endourology2022

DOI: 10.1089/end.2021.0956 PMID: 35331023

Combining CAPRA-S With Tumor IDC/C Features Improves the Prognostication of Biochemical Recurrence in Prostate Cancer Patients.

Jeyapala R, Kamdar S, Olkhov-Mitsel E, Zlotta A, Fleshner N, Visakorpi T, van der Kwast T, Bapat B

Clinical genitourinary cancer2022

DOI: 10.1016/j.clgc.2022.01.003 PMID: 35151601

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mentionMention their CIHR grant from 2023

Subject: Prospective PhD student: Artificial Intelligence Dear Professor Zlotta, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "Addition of immune checkpoint inhibitors to intravesical BCG for high-risk BCG-naïve non-muscle invasive bladder cancer: Systematic review and meta-analysis." (2026), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "Development, multi-ancestry international validation, algorithmic audit, and prospective silent trial evaluation of PRISM - A globally accessible, patient-oriented artificial intelligence-based model to predict the presence of clinically significant prostate cancer" (2023), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]

Something wrong or missing on this profile? Suggest a correction

Alexandre Zlotta

Research

Latest papers

Latest funding

Addition of immune checkpoint inhibitors to intravesical BCG for high-risk BCG-naïve non-muscle invasive bladder cancer: Systematic review and meta-analysis.

Prostate-specific antigen density does not predict metastatic disease on PSMA-PET in high-risk prostate cancer patients with negative conventional imaging.

Percentage of free to total PSA as a biomarker of survival in metastatic castration-resistant prostate cancer.

Optimizing biopsy decisions in PI-RADS 3 lesions: cross-institutional validation of a local clinical risk model.

Metabolic, cardiac, and bone health testing in patients with prostate cancer on androgen‐deprivation therapy: A population‐based assessment of adherence to therapeutic monitoring guidelines

Cost of Bladder Cancer Care: A Single-center Comparison of Radical Cystectomy and Trimodal Therapy.

Validating the total cancer location density metric for stratifying patients with low-risk localized prostate cancer at higher risk of grade group reclassification while on active surveillance.

Prostate biopsy in the era of MRI-targeting: towards a judicious use of additional systematic biopsy.

Factors Associated with Stent Change and Prognosis in Patients with Malignant Ureteral Obstruction.

Combining CAPRA-S With Tumor IDC/C Features Improves the Prognostication of Biochemical Recurrence in Prostate Cancer Patients.

Development, multi-ancestry international validation, algorithmic audit, and prospective silent trial evaluation of PRISM - A globally accessible, patient-oriented artificial intelligence-based model to predict the presence of clinically significant prostate cancer

Development of the first pre-operative serum exosomal miRNA test to guide treatment decision in prostate cancer

qTAP, A Novel Platform for Personalized Medicine in Cancer

Genetic, Epigenetic and Proteomic Analysis of the Kallikrein Family in Search for Novel Diagnostic Prognostic and Risk Susceptibility Algorithms for Prostate Cancer

Genetic, Epigenetic and Proteomic Analysis of the Kallikrein Family in Search for Novel Diagnostic Prognostic and Risk Susceptibility Algorithms for Prostate Cancer

Frequent collaborators

Antonio Finelli

Neil Fleshner

Girish Kulkarni

Nathan Perlis

Robert Hamilton

Alejandro Berlin

Bharati Bapat

Melissa Huynh

Aly-Khan Lalani

Paul Toren

Bobby Shayegan

Uri Tabori

Laurie Ailles

Shabbir Alibhai

Jason Moffat

Alexandre Zlotta

Research

Latest papers

Latest funding

Addition of immune checkpoint inhibitors to intravesical BCG for high-risk BCG-na&#xef;ve non-muscle invasive bladder cancer: Systematic review and meta-analysis.

Prostate-specific antigen density does not predict metastatic disease on PSMA-PET in high-risk prostate cancer patients with negative conventional imaging.

Percentage of free to total PSA as a biomarker of survival in metastatic castration-resistant prostate cancer.

Optimizing biopsy decisions in PI-RADS 3 lesions: cross-institutional validation of a local clinical risk model.

Metabolic, cardiac, and bone health testing in patients with prostate cancer on androgen‐deprivation therapy: A population‐based assessment of adherence to therapeutic monitoring guidelines

Cost of Bladder Cancer Care: A Single-center Comparison of Radical Cystectomy and Trimodal Therapy.

Validating the total cancer location density metric for stratifying patients with low-risk localized prostate cancer at higher risk of grade group reclassification while on active surveillance.

Prostate biopsy in the era of MRI-targeting: towards a judicious use of additional systematic biopsy.

Factors Associated with Stent Change and Prognosis in Patients with Malignant Ureteral Obstruction.

Combining CAPRA-S With Tumor IDC/C Features Improves the Prognostication of Biochemical Recurrence in Prostate Cancer Patients.

Development, multi-ancestry international validation, algorithmic audit, and prospective silent trial evaluation of PRISM - A globally accessible, patient-oriented artificial intelligence-based model to predict the presence of clinically significant prostate cancer

Development of the first pre-operative serum exosomal miRNA test to guide treatment decision in prostate cancer

qTAP, A Novel Platform for Personalized Medicine in Cancer

Genetic, Epigenetic and Proteomic Analysis of the Kallikrein Family in Search for Novel Diagnostic Prognostic and Risk Susceptibility Algorithms for Prostate Cancer

Genetic, Epigenetic and Proteomic Analysis of the Kallikrein Family in Search for Novel Diagnostic Prognostic and Risk Susceptibility Algorithms for Prostate Cancer

Frequent collaborators

Antonio Finelli

Neil Fleshner

Girish Kulkarni

Nathan Perlis

Robert Hamilton

Alejandro Berlin

Bharati Bapat

Melissa Huynh

Aly-Khan Lalani

Paul Toren

Bobby Shayegan

Uri Tabori

Laurie Ailles

Shabbir Alibhai

Jason Moffat

Addition of immune checkpoint inhibitors to intravesical BCG for high-risk BCG-naïve non-muscle invasive bladder cancer: Systematic review and meta-analysis.